½ÃÀ庸°í¼­
»óǰÄÚµå
1339173

¾ÐŸ¸Ó ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ ¹× »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2023-2032³â)

Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, Others); By Region, And Segment Forecasts, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 114 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠ¿¬±¸¿¡ µû¸£¸é, ¼¼°è ¾ÐŸ¸Ó ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 163¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¾ÐŸ¸ÓÀÇ ´ÙÀç´Ù´ÉÇÔ°ú ÇコÄɾî, »ý¸í°øÇÐ, Áø´Ü µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ ÀáÀçÀûÀÎ ÀÀ¿ë °¡´É¼ºÀÌ ¸¹Àº ±â¾÷µéÀÇ °ü½ÉÀ» ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ Ÿ°ÙÀ» À§ÇÑ ¸ÂÃãÇü ¾ÐŸ¸Ó°¡ °¡´ÉÇØÁö¸é¼­ ¾ÐŸ¸ÓÀÇ ¿ëµµ´Â ÀüÅëÀûÀÎ ¿¬±¸ ¹× Áø´Ü ºÐ¾ß ¿Ü¿¡µµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ä¡·áÁ¦¿Í ¹ÙÀÌ¿À¼¾¼­ µî ¾ÐŸ¸Ó¸¦ ±â¹ÝÀ¸·Î ÇÑ ½ÅÁ¦Ç°ÀÌ °³¹ßµÇ¾î ¾ÐŸ¸Ó ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

SELEX ±â¼úÀº SARS-CoV-2 ¹× Äڷγª19¿Í °ü·ÃµÈ ƯÁ¤ ¹ÙÀÌ¿À¸¶Ä¿¿¡ °áÇÕÇÒ ¼ö ÀÖ´Â ¾ÐŸ¸Ó¸¦ °³¹ßÇÏ¿© Áø´Ü ŰƮ ¹× ºÐ¼®¹ýÀ» °³¹ßÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ÐŸ¸Ó ±â¹Ý Áø´Ü µµ±¸´Â ¹ÙÀÌ·¯½º ¹× °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÃâ¿¡ ÀÖ¾î ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇÏ¿© Áúº´ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Áø´Ü ŰƮ ¹× ºÐ¼® ½ÃÀå µµÀÔÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2021³â 12¿ù, Achiko AGÀÇ Äڷγª19 Áø´ÜŰƮ Aptamex°¡ Àεµ³×½Ã¾Æ º¸°ÇºÎÀÇ ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç, Aptamex´Â DNA ¾ÐŸ¸Ó ±â¼ú·Î °³¹ßµÈ 2¼¼´ë Áø´ÜŰƮ·Î ºñ¿ë È¿À²ÀûÀ̰í È­ÇÐÀûÀ¸·Î ÇÕ¼ºµÈ ÀǾàǰ Áø´Ü ŰƮÀÔ´Ï´Ù.

½ÃÀå ¼ºÀåÀº ¹Ì±¹ FDA, ij³ª´Ù º¸°ÇºÎ, EMA, COFEPRIS, MHRA, CDSCO µî ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ßÀ» Áö¿øÇϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇÔÀ¸·Î½á ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 3¿ù ¹Ì±¹ FDA´Â AMD¿¡ À̾î Áö¸®Àû À§ÃàÁõ(GA) ȯÀÚ¸¦ À§ÇÑ Ä¡·áÁ¦·Î IVERIC BioÀÇ Áö¹«¶ó(Zimura)¸¦ ÆÐ½ºÆ®Æ®·¢(Fast Track) ÁöÁ¤Çß½À´Ï´Ù. Áö¹«¶ó(Zimura)´Â Æä±×È­ RNA ¾ÐŸ¸Ó(pegylated RNA aptamer)¸¦ ÇÕ¼ºÇÏ¿© À¯¸®Ã¼°­³» ÁÖ»ç·Î Åõ¿©Çϸç, AMD ¹ßº´ÀÇ ¿øÀÎÀ¸·Î ¾Ë·ÁÁø C5 ÀÎÀÚ¸¦ ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù.

¾ÐŸ¸Ó ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Áø´Ü, Ä¡·á, ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÇÙ»ê ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù.

¿¬±¸°³¹ß ºÐ¾ß´Â ¾ÐŸ¸Ó Á¦Á¶±â¾÷¿¡ ´ëÇÑ ³ôÀº °ü½É°ú Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀ¸·Î ½ÃÀå Á¡À¯À² 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

Áø´Ü ºÐ¾ß´Â Áúº´ÀÇ Á¶±â Áø´ÜÀ» À§ÇÑ ¾ÐŸ¸Ó ±â¹Ý Áø´Ü ŰƮ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¡Àå ºü¸¥ ¼ºÀå·üÀ» ±â·ÏÇß½À´Ï´Ù.

ºÏ¹Ì´Â ¾ÐŸ¸Ó °³¹ß¿¡ Á¾»çÇÏ´Â ±â¾÷ÀÇ Á¸Àç¿Í °úÇÐÀû Çõ½ÅÀ» À§ÇÑ °­·ÂÇÑ »êÇÐÇù·ÂÀ¸·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ë±Ô¸ð ȯÀÚ Ç®ÀÇ Á¸Àç, °Å´ëÇÑ ¹Ì°³Ã´ Àα¸, ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ Á¤Ã¥À¸·Î ÀÎÇØ ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®

  • ¾ÐŸ¸Ó ½ÃÀå - ¾÷°è ÇöȲ
  • ¾ÐŸ¸Ó ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PESTLE ºÐ¼®
  • ¾ÐŸ¸Ó ¾÷°è µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÇÙ»ê ¾ÐŸ¸Ó
  • ÆéƼµå ¾ÐŸ¸Ó

Á¦6Àå ¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Áø´Ü
  • Ä¡·áÇÐ
  • ¿¬±¸°³¹ß
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå, Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¾ÐŸ¸Ó ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
  • ¾ÐŸ¸Ó ½ÃÀå - ºÏ¹Ì
    • ºÏ¹Ì : ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • ºÏ¹Ì : ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾ÐŸ¸Ó ½ÃÀå - ¹Ì±¹
    • ¾ÐŸ¸Ó ½ÃÀå - ij³ª´Ù
  • ¾ÐŸ¸Ó ½ÃÀå - À¯·´
    • À¯·´ : ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • À¯·´ : ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾ÐŸ¸Ó ½ÃÀå - ¿µ±¹
    • ¾ÐŸ¸Ó ½ÃÀå - ÇÁ¶û½º
    • ¾ÐŸ¸Ó ½ÃÀå - µ¶ÀÏ
    • ¾ÐŸ¸Ó ½ÃÀå - ÀÌÅ»¸®¾Æ
    • ¾ÐŸ¸Ó ½ÃÀå - ½ºÆäÀÎ
    • ¾ÐŸ¸Ó ½ÃÀå - ³×´ú¶õµå
    • ¾ÐŸ¸Ó ½ÃÀå - ·¯½Ã¾Æ
  • ¾ÐŸ¸Ó ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾ÐŸ¸Ó ½ÃÀå - Áß±¹
    • ¾ÐŸ¸Ó ½ÃÀå - Àεµ
    • ¾ÐŸ¸Ó ½ÃÀå - ¸»·¹À̽þÆ
    • ¾ÐŸ¸Ó ½ÃÀå - ÀϺ»
    • ¾ÐŸ¸Ó ½ÃÀå - Àεµ³×½Ã¾Æ
    • ¾ÐŸ¸Ó ½ÃÀå - Çѱ¹
  • ¾ÐŸ¸Ó ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾ÐŸ¸Ó ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾ÐŸ¸Ó ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¾ÐŸ¸Ó ½ÃÀå - À̽º¶ó¿¤
    • ¾ÐŸ¸Ó ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
  • ¾ÐŸ¸Ó ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¾ÐŸ¸Ó ½ÃÀå, ¿ëµµº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¾ÐŸ¸Ó ½ÃÀå, À¯Çüº°, 2019-2032³â
    • ¾ÐŸ¸Ó ½ÃÀå - ¸ß½ÃÄÚ
    • ¾ÐŸ¸Ó ½ÃÀå - ºê¶óÁú
    • ¾ÐŸ¸Ó ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª

Á¦8Àå °æÀï ±¸µµ

  • È®Àå ¹× Àμö ºÐ¼®
    • È®Àå
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦9Àå ±â¾÷ °³¿ä

  • Base Pair Biotechnologies
  • SomaLogic
  • Aptadel Therapeutics
  • Aptamer Group
  • Noxxon Pharma
  • Aptagen
  • TriLink Biotechnologies
  • Altermune
  • Vivonics
  • AM Biotechnologies
LSH 23.10.19

The global aptamers market size is expected to reach USD 16.33 billion by 2032, according to a new study by Polaris Market Research. The report "Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, and Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, and Others); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Versatility of aptamers and their potential applications in various industries such as healthcare, biotechnology, and diagnostics have attracted the attention of many companies. Moreover, the availability of customized aptamers for specific targets has expanded the applications of aptamers beyond their traditional use in research and diagnostics. This has led to the development of new aptamer-based products, including therapeutics and biosensors, which are expected to further drive the growth of the aptamers market.

The SELEX technology has been used to develop aptamers that can bind to specific biomarkers related to SARS-CoV-2 and COVID-19, allowing for the development of diagnostic kits and assays. These aptamer-based diagnostic tools can provide high sensitivity and specificity in detecting the virus and related biomarkers, which can aid in disease diagnosis and monitoring. As a result, the introduction of such diagnostic kits and assays in the market is expected to drive the growth of the market.

In December 2021, Achiko AG's Aptamex, a COVID-19 diagnostic kit, received approval from the health ministry of Indonesia. Aptamex is a 2nd generation kit developed using DNA aptamer technology, which is cost-effective, chemically synthesized, diagnostic kit in the pharmaceuticals.

Market growth is further supported by various regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, & CDSCO, which have taken initiatives to support the research and development in this field. For example, in March 2020, the U.S. FDA granted Fast Track designation to IVERIC Bio's Zimura for the treatment of patients with geographic atrophy (GA) secondary to AMD. It is a pegylated RNA aptamer, which is synthesized & administered by the intra-vitreal injection. It works by the inhibition of factor C5, considered responsible for onset of AMD.

Aptamers Market Report Highlights

Nucleic acid segment dominated the market, owing to rapid development in the diagnostics, therapeutics, and advancements in the biomarker discovery

R&D segment accounted for the larger market share, as there is a strong interest in aptamer manufacturing companies, and favorable government initiatives

Diagnostic segment recorded fastest growth rate, owing to rising need for aptamer based diagnostic kits for the early disease diagnosis

North America garnered the largest share, owing to the presence of companies engaged in the development of aptamers, and strong industry academia collaboration for scientific breakthroughs

Asia Pacific is projected to register a higher growth rate, owing to the presence of large patient pool, huge untapped population, and favorable government policies for research.

The global players include: Base Pair Biotechnologies, SomaLogic, Aptadel Therapeutics, Aptamer Group, Noxxon Pharma, Aptagen, TriLink Biotechnologies, Altermune, Vivonics, and AM Biotechnologies.

Polaris Market Research has segmented the aptamers market report based on type, application, and region:

Aptamers, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Nucleic Acid Aptamer
  • Peptide Aptamer

Aptamers, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Diagnostics
  • Therapeutics
  • Research and Development
  • Others

Aptamers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Aptamers Market Insights

  • 4.1. Aptamers Market - Industry Snapshot
  • 4.2. Aptamers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising number of the advantages of aptamers over antibodies
      • 4.2.1.2.Rising prevalence of chronic and rare disease
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Growth in the venture capital funding for research on aptamers
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Aptamers Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Aptamers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Aptamers, by Type, 2019-2032 (USD Billion)
  • 5.3. Nucleic Acid Aptamer
    • 5.3.1. Global Aptamers Market, by Nucleic Acid Aptamer, by Region, 2019-2032 (USD Billion)
  • 5.4. Peptide Aptamer
    • 5.4.1. Global Aptamers Market, by Peptide Aptamer, by Region, 2019-2032 (USD Billion)

6. Global Aptamers Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Aptamers Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Diagnostics
    • 6.3.1. Global Aptamers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
  • 6.4. Therapeutics
    • 6.4.1. Global Aptamers Market, by Therapeutics, by Region, 2019-2032 (USD Billion)
  • 6.5. Research and Development
    • 6.5.1. Global Aptamers Market, by Research and Development, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Aptamers Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Aptamers Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Aptamers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Aptamers Market - North America
    • 7.3.1. North America: Aptamers Market, by Application, 2019-2032 (USD Billion)
    • 7.3.2. North America: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Aptamers Market - U.S.
      • 7.3.3.1. U.S.: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Aptamers Market - Canada
      • 7.3.4.1. Canada: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Aptamers Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Aptamers Market - Europe
    • 7.4.1. Europe: Aptamers Market, by Application, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Aptamers Market - UK
      • 7.4.3.1. UK: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Aptamers Market - France
      • 7.4.4.1. France: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Aptamers Market - Germany
      • 7.4.5.1. Germany: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Aptamers Market - Italy
      • 7.4.6.1. Italy: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Aptamers Market - Spain
      • 7.4.7.1. Spain: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Aptamers Market - Netherlands
      • 7.4.8.1. Netherlands: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Aptamers Market - Russia
      • 7.4.9.1. Russia: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Aptamers Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Aptamers Market - Asia Pacific
    • 7.5.1. Asia Pacific: Aptamers Market, by Application, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Aptamers Market - China
      • 7.5.3.1. China: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Aptamers Market - India
      • 7.5.4.1. India: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Aptamers Market - Malaysia
      • 7.5.5.1. Malaysia: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Aptamers Market - Japan
      • 7.5.6.1. Japan: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Aptamers Market - Indonesia
      • 7.5.7.1. Indonesia: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Aptamers Market - South Korea
      • 7.5.8.1. South Korea: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Aptamers Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Aptamers Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Aptamers Market, by Application, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Aptamers Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Aptamers Market - UAE
      • 7.6.4.1. UAE: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Aptamers Market - Israel
      • 7.6.5.1. Israel: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Aptamers Market - South Africa
      • 7.6.6.1. South Africa: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Aptamers Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Aptamers Market - Latin America
    • 7.7.1. Latin America: Aptamers Market, by Application, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Aptamers Market - Mexico
      • 7.7.3.1. Mexico: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Aptamers Market - Brazil
      • 7.7.4.1. Brazil: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Aptamers Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Aptamers Market - Argentina
      • 7.7.5.1. Argentina: Aptamers Market, by Application, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Aptamers Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Base Pair Biotechnologies
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. SomaLogic
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Aptadel Therapeutics
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Aptamer Group
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Noxxon Pharma
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Aptagen
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. TriLink Biotechnologies
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Altermune
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Vivonics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. AM Biotechnologies
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦